Scarica l'app Stockscreener
13.87
7.94%
1.02
Precedente Chiudi:
$12.85
Aprire:
$12.9
Volume 24 ore:
604.25K
Relative Volume:
1.03
Capitalizzazione di mercato:
$702.14M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-2.6369
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
+5.40%
1M Prestazione:
+19.57%
6M Prestazione:
+35.98%
1 anno Prestazione:
+59.06%
Intervallo 1D:
$12.69
$14.24
Intervallo di 1 settimana:
$12.61
$14.24
Portata 52W:
$5.035
$14.24
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta RGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
13.87 | 650.51M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer - TipRanks
REGENXBIO (NASDAQ:RGNX) Stock Price Up 5.2%Time to Buy? - MarketBeat
(RGNX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
REGENXBIO (NASDAQ:RGNX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Wet Age-Related Macular Degeneration Market Growth - openPR.com
Voss Capital LP Boosts Stock Holdings in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. $RGNX is 22NW LP's 5th Largest Position - MarketBeat
Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser
What insider trading reveals about REGENXBIO Inc. stockJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
Why global investors buy REGENXBIO Inc. (RB0) stock2025 Market WrapUp & Safe Capital Allocation Plans - Newser
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulus2025 Big Picture & Safe Entry Zone Identification - Newser
Can REGENXBIO Inc. stock resist market sell offsQuarterly Profit Review & Technical Pattern Based Signals - Newser
Is REGENXBIO Inc. stock resilient to inflationGold Moves & Fast Exit Strategy with Risk Control - Newser
JPMorgan Chase & Co. Sells 512,318 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. (RB0) stock see valuation expansionWeekly Trade Analysis & Reliable Trade Execution Plans - Newser
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights
How (RGNX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
26,773 Shares in REGENXBIO Inc. $RGNX Bought by Rockefeller Capital Management L.P. - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Gainers Report: Is REGENXBIO Inc. stock a contrarian buyJuly 2025 Summary & Risk Managed Trade Strategies - moha.gov.vn
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript - The Globe and Mail
Regenxbio files $300M mixed securities shelf - MSN
Transcript : REGENXBIO Inc. Presents at Stifel 2025 Healthcare Conference, Nov-11-2025 01 - marketscreener.com
Regenxbio files $300M mixed shelf offering - MSN
Regenxbio (RGNX) Files for $300M Securities Offering - GuruFocus
Regenxbio files for mixed shelf of up to $300 millionSEC filing - marketscreener.com
[S-3] REGENXBIO Inc. Shelf Registration Statement | RGNX SEC FilingForm S-3 - Stock Titan
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛
REGENXBIO to Participate in Upcoming Investor Conference - PR Newswire
REGENXBIO (Nasdaq: RGNX) Fireside Chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN
Brokers Set Expectations for REGENXBIO FY2026 Earnings - MarketBeat
REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital - MarketBeat
RGNX S-8及美國證券交易委員會申報文件 - Yahoo 財經
Chardan Capital Maintains Buy Rating for RGNX with $52 Price Tar - GuruFocus
Is REGENXBIO Inc. (RB0) stock safe for risk averse investors2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Will REGENXBIO Inc. (RB0) stock profit from AI boomJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com
How REGENXBIO Inc. stock responds to policy changes2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
Visualizing REGENXBIO Inc. stock with heatmapsWeekly Trade Recap & Intraday High Probability Alerts - newser.com
Reversal indicators forming on REGENXBIO Inc. stock2025 Breakouts & Breakdowns & Intraday High Probability Alerts - newser.com
Trading Systems Reacting to (RGNX) Volatility - news.stocktradersdaily.com
Will REGENXBIO Inc. stock split again soonTrade Ideas & Precise Buy Zone Tips - newser.com
What data driven models say about REGENXBIO Inc.’s futurePortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):